Skip to content
Screener

AnaptysBio, Inc. ANAB Q4 2025 Annual earnings

Reported March 3, 2026 · Before market open

Revenue$108.2MBeat by $21.2M
EPS$1.58Beat by $0.69
Revenue estimate$87.0M
EPS estimate$0.89

Next report

Nov 10, 2026 (in 2 months)
Revenue estimate$14.0M
EPS estimate$0.11

Financials

Q4 2025

Income statement

See full
Revenue$108.2M+151%
Operating income$66.9M+792%

Balance sheet

See full
Cash & equivalents$238.2M+93.5%
Total debt$14.1K-99.9%
Total equity$37.2M-47.5%
Total assets$364.4M-24.7%

Cash flow

See full
Operating cash flow$98.0M+247%
CapEx$1.0K-99.6%
Free cash flow$98.0M+246%

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$1.34B+233%
Enterprise value$1.1B+273%
P/S5.7×+1.3×

Profitability

See full
Operating margin20.4%+11.0pp
FCF margin8.4%+4.3pp

Returns & leverage

See full
Debt / equity0×-0.2×
Current ratio9.1×-0.4×

FAQ

When did AnaptysBio, Inc. report Q4 2025 earnings?
AnaptysBio, Inc. (ANAB) reported Q4 2025 earnings on March 3, 2026 before market open.
What were AnaptysBio, Inc.'s Q4 2025 revenue and EPS?
AnaptysBio, Inc. reported revenue of $108.2M and eps of $1.58 for Q4 2025.
Did AnaptysBio, Inc. beat estimates in Q4 2025?
Revenue beat the consensus estimate of $87.0M by $21.2M. EPS beat the consensus estimate of $0.89 by $0.69.
How did AnaptysBio, Inc.'s Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 151.1% from $43.1M a year earlier.
Where can I find AnaptysBio, Inc.'s Q4 2025 SEC filings?
You can read the 8-K earnings release (0001193125-26-088239) and the 10-K periodic report (0001193125-26-088290) directly on SEC EDGAR. The filing index links above go to sec.gov.